Evidence map›Paper›PMID 34363714›Full record

ArticleCancer science2021

The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation.

Shunichi Toki, Tetsuro Yoshimaru, Yosuke Matsushita, Hitoshi Aihara, Masaya Ono, Koichi Tsuneyama, Koichi Sairyo, Toyomasa Katagiri

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. miR-30 inhibits the progression of osteosarcoma by targeting MTA1.Journal of musculoskeletal & neuronal interactions · 2022
    Article
  8. Article
  9. Prohibitins: A Key Link between Mitochondria and Nervous System Diseases.Oxidative medicine and cellular longevity · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shunichi TokiDivision of Genome Medicine, Advanced Institute of Medical Sciences, Tokushima University, Tokushima, Japan.
Tetsuro YoshimaruDivision of Genome Medicine, Advanced Institute of Medical Sciences, Tokushima University, Tokushima, Japan.
Yosuke MatsushitaDivision of Genome Medicine, Advanced Institute of Medical Sciences, Tokushima University, Tokushima, Japan.
Hitoshi AiharaDivision of Genome Medicine, Advanced Institute of Medical Sciences, Tokushima University, Tokushima, Japan.
Masaya OnoDepartment of Proteomics, National Cancer Center Research Institute, Tokyo, Japan.
Koichi TsuneyamaDepartment of Pathology and Laboratory Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Koichi SairyoDepartment of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Toyomasa KatagiriDivision of Genome Medicine, Advanced Institute of Medical Sciences, Tokushima University, Tokushima, Japan.ORCID https://orcid.org/0000-0001-5086-7444
Tokushima University · JP

Funding

Japan Agency for Medical Research and Development 19191248Ministry of Education, Culture, Sports, Science and Technology JP16H05153Ministry of Education, Culture, Sports, Science and Technology JP17H06419Ministry of Education, Culture, Sports, Science and Technology JP18K07200Ministry of Education, Culture, Sports, Science and Technology JP20H00543
6 · The paper itself

Abstract

Previous studies reported the critical role of the brefeldin A-inhibited guanine nucleotide exchange protein 3-prohibitin 2 (BIG3-PHB2) complex in modulating estrogen signaling activation in breast cancer cells, yet its pathophysiological roles in osteosarcoma (OS) cells remain elusive. Here, we report a novel function of BIG3-PHB2 in OS malignancy. BIG3-PHB2 complexes were localized mainly in mitochondria in OS cells, unlike in estrogen-dependent breast cancer cells. Depletion of endogenous BIG3 expression by small interfering RNA (siRNA) treatment led to significant inhibition of OS cell growth. Disruption of BIG3-PHB2 complex formation by treatment with specific peptide inhibitor also resulted in significant dose-dependent suppression of OS cell growth, migration, and invasion resulting from G2/M-phase arrest and in PARP cleavage, ultimately leading to PARP-1/apoptosis-inducing factor (AIF) pathway activation-dependent apoptosis in OS cells. Subsequent proteomic and bioinformatic pathway analyses revealed that disruption of the BIG3-PHB2 complex might lead to downregulation of inner mitochondrial membrane protein complex activity. Our findings indicate that the mitochondrial BIG3-PHB2 complex might regulate PARP-1/AIF pathway-dependent apoptosis during OS cell proliferation and progression and that disruption of this complex may be a promising therapeutic strategy for OS.

Indexed as

AnimalsApoptosisApoptosis Inducing FactorBone NeoplasmsCell Line, TumorCell MovementCell-Penetrating PeptidesCell ProliferationCell SurvivalDatabases, FactualDown-RegulationG2 Phase Cell Cycle CheckpointsGene SilencingGuanine Nucleotide Exchange FactorsHumansMembrane ProteinsApoptosis Inducing FactorARFGEF3 protein, humanCell-Penetrating PeptidesERAP peptideGuanine Nucleotide Exchange FactorsMembrane ProteinsPARP1 protein, humanPHB2 protein, humanPhb2 protein, mousePoly (ADP-Ribose) Polymerase-1ProhibitinsRepressor ProteinsRNA, Small InterferingBIG3mitochondriaosteosarcomapeptide inhibitorPHB2

Identifiers

PMID34363714
PMCPMC8486206
OpenAlexW3191846462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.